Great Lakes Advisors LLC Lowers Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Great Lakes Advisors LLC lessened its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 50.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 136,183 shares of the biotechnology company's stock after selling 140,351 shares during the quarter. Great Lakes Advisors LLC owned 0.05% of Iovance Biotherapeutics worth $1,107,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Diversified Trust Co lifted its stake in Iovance Biotherapeutics by 12.3% in the fourth quarter. Diversified Trust Co now owns 13,512 shares of the biotechnology company's stock valued at $110,000 after acquiring an additional 1,481 shares during the last quarter. Raymond James & Associates increased its position in Iovance Biotherapeutics by 29.7% during the fourth quarter. Raymond James & Associates now owns 16,910 shares of the biotechnology company's stock worth $137,000 after buying an additional 3,868 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Iovance Biotherapeutics by 21.1% during the third quarter. Victory Capital Management Inc. now owns 22,598 shares of the biotechnology company's stock valued at $103,000 after buying an additional 3,937 shares in the last quarter. Carnegie Capital Asset Management LLC lifted its position in shares of Iovance Biotherapeutics by 17.1% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 27,400 shares of the biotechnology company's stock worth $223,000 after buying an additional 4,000 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in shares of Iovance Biotherapeutics by 24.8% during the 3rd quarter. Amalgamated Bank now owns 22,306 shares of the biotechnology company's stock worth $101,000 after acquiring an additional 4,434 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company's stock.

Analyst Ratings Changes

IOVA has been the subject of several analyst reports. Chardan Capital boosted their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a report on Tuesday, February 20th. The Goldman Sachs Group lifted their target price on shares of Iovance Biotherapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Wells Fargo & Company raised their price target on Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, March 1st. StockNews.com upgraded Iovance Biotherapeutics to a "sell" rating in a research note on Friday, February 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Friday, May 10th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.64.

Iovance Biotherapeutics Trading Up 0.1 %

IOVA stock traded up $0.01 during midday trading on Wednesday, hitting $10.33. The stock had a trading volume of 5,271,897 shares, compared to its average volume of 7,960,216. Iovance Biotherapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $18.33. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -5.74 and a beta of 0.66. The stock has a 50-day simple moving average of $12.73 and a 200 day simple moving average of $10.22.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.03. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.99 million. Iovance Biotherapeutics had a negative return on equity of 71.45% and a negative net margin of 23,615.70%. Iovance Biotherapeutics's quarterly revenue was up 71400.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.50) EPS. On average, equities analysts forecast that Iovance Biotherapeutics, Inc. will post -1.37 EPS for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.